Aegean Conferences is an independent, nonprofit, educational organization directed and managed by the scientific community. The board is made up of nine researchers/scientists in various disciplines from Harvard, Brown, University of Pennsylvania, UCSD, Princeton, Biovista and the Foundation for Biomedical Research Academy of Athens. The board both invites and approves unsolicited proposals for Conferences in all fields of Science, Engineering, Arts, and Humanities. The purpose of the Conferences is to bring together individuals with common interests to examine the emerging and most advanced aspects of their particular field.The Symposium on Ovarian Cancer: State of the Art and Future Directions intends to bring together international experts interested in the development of novel diagnostic, prognostic and therapeutic tools for ovarian cancer. The meeting will function as a think tank where clinicians, translational and basic scientists, and parties from the biotechnology and pharmaceutical industry will get together to review recent advances in clinical research and translational science in ovarian cancer and define areas of future research opportunities and priorities.

Ovarian Cancer Detection and Pathogenesis 1 Potential &limitations in early diagnosis of Ovarian cancer N Urban 2 SMRP and HE4 as biomarker for Ovarian carcinoma I Hellstorm 3 Classification of Ovarian cancer: A genomic analysis MJ Birrer 4 Epigenetic markers of ovarian cancer PM O¿Brien 5 Role of genetic polymorphisms in ovarian cancer susceptibility: development of an international ovarian cancer association consortium A Berchuck 6 microRNA in human cancer: One step forward in diagnosis and treatment L Zhang 7 Ovarian carcinogenesis, an alternative hypotheses JMJ Piek 8 BRCA1 induced Ovarian oncogenesis. L Dubeau 9 Role of p53 and Rb in ovarian cancer A Nikitin 10 Ovulatory factor in ovarian carcinogenesis. W Murdoch Ovarian Cancer Therapeutics 11 Gynecologic Oncology group trials in Ovarian Cancer R Ozols 12 Platinum Combinations for frontline chemotherapy of advanced ovarian carcinoma G Aravantinos 13 Intraperitoneal chemotherapy of Ovarian Cancer M Morgan 14 Ovarian cancer- can we reverse drug resistance? S Kaye 15 Nanoparticulate Paclitaxel, Nanotax, in ovarian cancer PF Terranova 16 Individualized molecular Medicine: Targeting the p13K pathway. G Mills 17 Defective Apoptosis underlies chemoresistance in Ovarian Cancer R Liu 18 Nanoparticle delivery of suicide DNA for epithelial Ovarian cancer therapy. JA Sawicki 19 Biological therapy with oncolytic Herpes virus F Benencia 20 Cancer immunotherapy:Perspectives & prospects MPapamichail 21 Regulatory T cells: A New Frontier in Cancer Immunotherapy T curiel 22 Inhibitory B7 family members in human ovarian carcinoma. WZou 23 Vascular leukocytes: a new target in ovarian cancer. G Coukos 24 Heparin-binding EGF-like growth factor as a new target molecule for cancer therapy E Mekada